Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.46 |
| ▸ | MAPT | P10636 | 7/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 7/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.40 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.40 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1202360 | 0.93 | MAPT (0.47) | ALDH1A1KDM4EMAPTSMN1; SMN2RAB9A | |
| SCHEMBL1202226 | 0.91 | MAPT (0.49) | ALDH1A1KDM4EMAPTSMN1; SMN2RAB9A | |
| SCHEMBL1202485 | 0.90 | MAPT (0.52) | ALDH1A1KDM4EMAPTSMN1; SMN2RAB9A | |
| SCHEMBL1201988 | 0.89 | MAPT (0.48) | ALDH1A1KDM4EMAPTSMN1; SMN2RAB9A | |
| SCHEMBL1201675 | 0.89 | GAA (0.44) | ALDH1A1KDM4EMAPTSMN1; SMN2RAB9A | |
| SCHEMBL1201959 | 0.88 | MAPT (0.47) | ALDH1A1KDM4EMAPTSMN1; SMN2RAB9A | |
| SCHEMBL2076565 | 0.88 | ALDH1A1 (0.49) | ALDH1A1KDM4EMAPTSMN1; SMN2RAB9A | |
| SCHEMBL1202499 | 0.88 | ALDH1A1 (0.47) | ALDH1A1KDM4EMAPTSMN1; SMN2RAB9A | |
| SCHEMBL1201933 | 0.88 | ALDH1A1 (0.47) | ALDH1A1KDM4EMAPTSMN1; SMN2RAB9A | |
| SCHEMBL1201658 | 0.88 | GAA (0.43) | ALDH1A1KDM4EMAPTSMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946259-B2 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140066477-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-03-06 | — | — | US | disclosed |
| EP-2457901-A1 | Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors | High Point Pharmaceuticals, LLC (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20110065713-A1 | Benzazole Derivatives, Compositions, and Methods of Use as B-Secretase Inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-03-17 | — | — | US | disclosed |
| US-20110065713-A1 | Benzazole Derivatives, Compositions, and Methods of Use as B-Secretase Inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-03-17 | — | — | US | disclosed |
| US-7893267-B2 | Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893267-B2 | Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893267-B2 | Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-02-22 | — | — | US | disclosed |
| US-20090326006-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | VTVX HOLDINGS II LLC | 2009-12-31 | — | — | US | disclosed |
| US-20090326006-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | VTVX HOLDINGS II LLC | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326006-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | BACE1, BACE2, APP | ALDH1A1 1717/4885KDM4E 3510/4885MAPT 85/4885 |
| US-20110065713-A1 | Benzazole Derivatives, Compositions, and Methods of Use as B-Secretase Inhibitors | BACE1, BACE2, APP | ALDH1A1 2426/4885KDM4E 3536/4885MAPT 102/4885 |
| US-20140066477-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | BACE1, BACE2, APP | ALDH1A1 1717/4885KDM4E 3510/4885MAPT 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.